T2	Disease_disorder 168 170	MI
E1	Disease_disorder:T2 
T3	Qualitative_concept 162 167	acute
R1	MODIFY Arg1:T3 Arg2:E1	
T1	Age 24 35	54-year-old
T4	Gender 36 42	female
T5	Activity 47 55	admitted
E2	Activity:T5 
T6	Disease_disorder 107 109	HF
E3	Disease_disorder:T6 
T7	Diagnostic_procedure 184 204	coronary angiography
E4	Diagnostic_procedure:T7 
T8	Diagnostic_procedure 356 377	coronary intervention
E5	Diagnostic_procedure:T8 
T9	Time 137 156	three years earlier
E6	Time:T9 
*	OVERLAP E6 E1
T10	Anatomical_structure 229 250	right coronary artery
T11	Anatomical_structure 288 319	left descending coronary artery
T12	Disease_disorder 408 410	MI
E7	Disease_disorder:T12 
T13	Diagnostic_procedure 1387 1426	Cardiovascular magnetic resonance (CMR)
E8	Diagnostic_procedure:T13 
T14	Time 379 401	During hospitalisation
E9	Time:T14 
T15	Severity 456 531	Class III according to the New York Heart Association (NYHA) classification
T16	Disease_disorder 212 221	occlusion
E10	Disease_disorder:T16 
T17	Severity 206 211	total
R2	MODIFY Arg1:T17 Arg2:E10	
T18	Activity 342 351	undergone
E11	Activity:T18 
T19	Disease_disorder 976 979	CAD
E12	Disease_disorder:T19 
T20	Disease_disorder 996 1017	arterial hypertension
E13	Disease_disorder:T20 
T21	Disease_disorder 1019 1040	hypercholesterolaemia
E14	Disease_disorder:T21 
T22	Disease_disorder 1042 1064	ventricular arrhythmia
E15	Disease_disorder:T22 
T23	Medication 1066 1076	carvedilol
E16	Medication:T23 
T24	Medication 1078 1086	ramipril
E17	Medication:T24 
T25	Medication 1088 1102	spironolactone
E18	Medication:T25 
T26	Medication 1104 1114	furosemide
E19	Medication:T26 
T27	Medication 1116 1128	atorvastatin
E20	Medication:T27 
T28	Medication 1130 1143	trimetazidine
E21	Medication:T28 
T29	Medication 1145 1152	aspirin
E22	Medication:T29 
T30	Time 1155 1171	Two months later
E23	Time:T30 
T31	Activity 1184 1193	admission
E24	Activity:T31 
T32	Lab_value 1255 1275	NT-proBNP 1869 pg/mL
T33	Lab_value 583 646	Nterminal-pro-brain natriuretic peptide (NT-proBNP, 10581 pg/mL
T34	Lab 565 573	elevated
E25	Lab:T34 
A1	TREND E25 INC
T35	Disease_disorder 1625 1634	infection
E26	Disease_disorder:T35 
T36	Disease_disorder 1638 1643	fever
E27	Disease_disorder:T36 
T37	Lab 1604 1606	no
E28	Lab:T37 
A2	POLARITY E28 NEG
T38	Diagnostic_procedure 1853 1869	Echocardiography
E29	Diagnostic_procedure:T38 
T39	Diagnostic_procedure 2069 2096	endomyocardial biopsy (EMB)
E30	Diagnostic_procedure:T39 
T40	Diagnostic_procedure 2111 2114	EMB
E31	Diagnostic_procedure:T40 
T41	Disease_disorder 2564 2566	HF
E32	Disease_disorder:T41 
T42	Disease_disorder 2571 2574	CAD
E33	Disease_disorder:T42 
T43	Time 2679 2695	hree months late
E34	Time:T43 
T44	Activity 2713 2727	rehospitalised
E35	Activity:T44 
T45	Disease_disorder 2739 2741	HF
E36	Disease_disorder:T45 
T46	Severity 2742 2754	exacerbation
R3	MODIFY Arg1:E36 Arg2:T46	
T47	Lab_value 2772 2792	NT-proBNP 1980 pg/dL
T48	Lab_value 2794 2810	troponin 3 ng/mL
T49	Diagnostic_procedure 2891 2920	24-hour Holter ECG monitoring
E37	Diagnostic_procedure:T49 
T50	Lab_value 2812 2823	LVEDD 77 mm
T51	Lab_value 2825 2833	LVEF 30%
T52	Diagnostic_procedure 2330 2349	Electron microscopy
E38	Diagnostic_procedure:T52 
T53	Diagnostic_procedure 2938 2958	coronary angiography
E39	Diagnostic_procedure:T53 
T54	Lab 3084 3138	real-time polymerase chain reaction examination (qPCR)
E40	Lab:T54 
T55	Disease_disorder 3313 3333	viral cardiomyopathy
E41	Disease_disorder:T55 
T56	Medication 3394 3406	interferon-β
E42	Medication:T56 
T57	Dosage 3457 3474	62.5 μg (0.25 mL)
T58	Dosage 3494 3508	125 μg (0.5 mL
T59	Dosage 3545 3563	187.5 μg (0.75 mL)
T60	Administration 3564 3578	subcutaneously
T61	Time 3647 3659	fourth month
E43	Time:T61 
T62	Diagnostic_procedure 3678 3681	EMB
E44	Diagnostic_procedure:T62 
T63	Time 3759 3769	six months
E45	Time:T63 
T64	Medication 3788 3800	interferon-β
E46	Medication:T64 
T65	Severity 1240 1254	NYHA class II,
T67	Lab_value 1290 1298	LVEF 35%
T66	Lab_value 1277 1288	LVEDD 73 mm
T68	Disease_disorder 2019 2030	myocarditis
E47	Disease_disorder:T68 
T69	Time 4053 4061	two-year
E48	Time:T69 
T70	Activity 4062 4071	follow-up
E49	Activity:T70 
T71	Qualitative_concept 4076 4086	uneventful
R4	MODIFY Arg1:E49 Arg2:T71	
R5	MODIFY Arg1:E48 Arg2:E49	
